Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
40.45
-1.50 (-3.58%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Rapport Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Rapport Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $62.05. The average 1-year stock price forecast is 53.40% higher than the current stock price, while the lowest is $50 (+23.61%) and the highest is $80 (+97.78%).
Price Target: $62.05 (+53.40%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Rapport Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 11 | 12 | 12 | 12 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JonesTrading | JonesTrading | Buy Maintains $50 | Buy | Maintains | $50 | +23.61% | Sep 16, 2026 |
| BTIG | BTIG | Buy Reiterates $65 → $75 | Buy | Reiterates | $65 → $75 | +85.41% | Sep 16, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $56 | Buy | Reiterates | $56 | +38.44% | Sep 16, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 15, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 20, 2026 |
Financial Forecast
Revenue This Year
20.00M
Revenue Next Year
n/a
from 20.00M
Decreased by -100.00%
EPS This Year
-4.09
from -2.86
EPS Next Year
-5.23
from -4.09
EPS and Forward PE are based on non-GAAP adjusted numbers.